Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

Running, not enrolling

Conditions studied: Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II

In brief

Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.

Key facts

Study ID

NCT04628871

Run by

Sangamo Therapeutics

People needed

13

Starts

2020-11-03

Expected to finish

2030-01-01

Last updated by the study team

2024-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who received SB-318 under Study Protocol SB-318-1502, SB-913 under Study Protocol SB-913-1602, or SB-FIX under Study Protocol SB-FIX-1501
• Subjects who have provided consent to participate in the LTFU study.

You may not qualify if…

• Unable to comply with study visit schedule or study visit procedures.
• Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.

Where it is running

• UCSF Benioff Children's Hospital Oakland — Oakland, California, United States
• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
• New York University Grossman School of Medicine — New York, New York, United States
• University of North Carolina — Chapel Hill, North Carolina, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.